Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

作     者：Lin Shen 

作者机构：Department of Gastrointestinal OncologyKey Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteFu-Cheng Road 52Hai-Dian DistrictBeijing 100142China 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2018年第38卷第1期

页      面：770-772页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：HER2 trastuzumab chemotherapy 

摘      要：Human epidermal growth factor receptor 2(HER2)over-expression/amplification affects about 6.1%-23.0%of gastric cancer patients[1,2].All major guidelines rec-ommend HER2 testing to guide the selection for trastu-zumab treatment in metastatic gastric cancer(mGC)[3],because doublet chemotherapy with trastuzumab sig-nificantly improved overall survival(OS)in the crucial trastuzumab for gastric cancer trial(the ToGA trial)[4].However,the unsatisfactory gain of median progression-free survival(PFS)stresses important issues of intrinsic and acquired resistance to HER2-targeted therapies[4].Currently,the underlying molecular mechanism of tras-tuzumab resistance in mGC is still unclear,and the strat-egies to real time monitor resistance-specific aberrations are urgently needed.